<p>Tumour plasma perfusion (F<sub>p</sub>) in relation to overall survival (a), disease specific survival (b) and locoregional control (c). Nodal plasma perfusion in relation to survival (d) disease specific survival (e) and locoregional control (f).</p

Bernstein, Jonathan M

Bonington, Suzanne C

Carrington, Bernadette M

Homer, Jarrod J

Kershaw, Lucy E

Lowe, Natalie M

Mais, Kathleen

Slevin, Nicholas J

West, Catharine M

Withey, Stephanie B

PLoS ONE

Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes.A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response.Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23-49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21).DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients

Natalie M Lowe

Lucy E Kershaw

Jonathan M Bernstein

Stephanie B Withey

Kathleen Mais

Jarrod J Homer

Nicholas J Slevin

Suzanne C Bonington

Bernadette M Carrington

Catharine M West

Directory of Open Access Journals

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.

RECIST response to induction chemotherapy in relation to overall survival (a), disease specific survival (b) and locoregional control (c).</p

Natalie M. Lowe (5029574)

Lucy E. Kershaw (5029586)

Jonathan M. Bernstein (3805204)

Stephanie B. Withey (5029589)

Kathleen Mais (5029577)

Jarrod J. Homer (257011)

Nicholas J. Slevin (837616)

Suzanne C. Bonington (5029583)

Bernadette M. Carrington (5029580)

Catharine M. West (5029592)

The Francis Crick Institute

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy - Fig 3

Tumour plasma perfusion (Fp) in relation to overall survival (a), disease specific survival (b) and locoregional control (c). Nodal plasma perfusion in relation to survival (d) disease specific survival (e) and locoregional control (f).</p

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy - Fig 2

Natalie M. Lowe

Lucy E. Kershaw

Jonathan M. Bernstein

Stephanie B. Withey

Jarrod J. Homer

Nicholas J. Slevin

Suzanne C. Bonington

Bernadette M. Carrington

Catharine M. West

Crossref

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy

OBJECTIVES: Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes.METHODS: A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response.RESULTS: Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23-49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p&gt;0.21).CONCLUSION: DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients.</p

Edinburgh Research Explorer

Objectives Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes. Methods A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response. Results Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23–49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p&gt;0.21). Conclusion DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patient

Lowe, Natalie

Kershaw, Lucy

Homer, Jarrod

Slevin, Nicholas

Bonington, Suzanne C.

West, Catharine

The University of Manchester - Institutional Repository

Results from univariable analyses using Cox regression.

https://figshare.com/articles/Pre-treatment_tumour_perfusion_parameters_and_initial_RECIST_response_do_not_predict_long-term_survival_outcomes_for_patients_with_head_and_neck_squamous_cell_carcinoma_treated_with_induction_chemotherapy_-_Fig_3/6055925

Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

The Francis Crick Institute

The Francis Crick Institute

Crossref

Edinburgh Research Explorer

The University of Manchester - Institutional Repository

The Francis Crick Institute

The University of Manchester - Institutional Repository